Calvert Investment Management’s Genetic Technologies Ltd. GENE Stock Holding History

Calvert Investment Management’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-108	Closed	-$11K	–	605
2014 Q2	$11K	Buy	108 +2	+2%	+$239	﹤0.01%	357
2014 Q1	$15K	Buy	+106	New	+$17K	﹤0.01%	348

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Calvert Investment Management's GENE Position: Q3 2014 in Review

Calvert Investment Management sold out of Genetic Technologies Ltd. (GENE) in Q3 2014, closing a stake of 108 shares — an estimated $11K sold.

Calvert Investment Management first reported a position in GENE in Q1 2014 and held it in 2 quarters. The position peaked at $15K in Q1 2014. 6 funds tracked by Wall St. Rank hold GENE as of Q3 2014.

Calvert Investment Management reported no remaining Genetic Technologies Ltd. position as of Q3 2014 after selling out during the quarter.
Calvert Investment Management sold 108 Genetic Technologies Ltd. shares in Q3 2014, an estimated $11K.
Calvert Investment Management first reported a position in Genetic Technologies Ltd. in Q1 2014 and held it in 2 quarters.
Calvert Investment Management's Genetic Technologies Ltd. position peaked at $15K in Q1 2014.
6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2014.

Based on Calvert Investment Management's 13F filing for Q3 2014, filed 4 Nov 2014.